Notice2023-27114
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
December 11, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 236 (Monday, December 11, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 236 (Monday, December 11, 2023)]
[Notices]
[Pages 85894-85895]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-27114]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
[[Page 85895]]
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Theodoric Mattes at 240-627-3827, or
<a href="/cdn-cgi/l/email-protection#97e3fff2f8f3f8e5fef4b9faf6e3e3f2e4d7f9feffb9f0f8e1"><span class="__cf_email__" data-cfemail="daaeb2bfb5beb5a8b3b9f4b7bbaeaebfa99ab4b3b2f4bdb5ac">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Recombinant IgG Monoclonal Antibody-Based Detection of Taenia Antigen
In Humans And Pigs
Description of Technology: The pork tapeworm, Taenia solium, is
endemic in most of Asia, Latin America, and Sub-Saharan Africa. The
risk of infection is increased in regions where pigs are raised in
closed proximity to humans, with migration from endemic regions being
directly proportional to the prevalence of infection in high-income
countries. Human infection by T. solium occurs following oral ingestion
of eggs passed in human feces from an infected carrier. The larvae can
travel anywhere in the human body. Neurocysticercosis (NCC) occurs when
the larvae traverse the blood-brain barrier and penetrate the central
nervous system. Diagnosis of NCC is typically made through radiological
imaging studies (such as computed tomography or magnetic resonance
imaging) to visualize the morphology, stage, and location of the cysts.
Investigators at NIAID have developed the recombinant IgG
monoclonal antibody known as TsG10, which can target T. solium
circulating antigens. An expression vector to produce TsG10 is
available for expression in mammalian cell lines. The resulting
construct allows for a scalable, repeatable, and broadly accessible
production of monoclonal antibodies for both human and veterinary use.
The TsG10 monoclonal antibodies are adaptable for plate-based
diagnostic assays like ELISAs, to support a diagnosis of NCC.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Plate-based diagnostic immunoassays, both human and
veterinary, for the detection of T. solium circulating antigen
<bullet> Production of TsG10 recombinant monoclonal antibodies
Competitive Advantages:
<bullet> Detection of active T. solium infection
<bullet> Scalable and repeatable production of a monoclonal antibody
targeting T. solium
<bullet> Materials available for development or licensing
Development Stage:
<bullet> Research Material
Inventors: Drs. Thomas B. Nutman, Elise O'Connell, Theodore E.
Nash, Siddhartha Mahanty, Hector Garcia, Adriana Paredes, all of NIAID
Intellectual Property: HHS Reference No. E-043-2022-0
Licensing Contact: To license this technology, please contact
Theodoric Mattes at 240-627-3827, or <a href="/cdn-cgi/l/email-protection#96e2fef3f9f2f9e4fff5b8fbf7e2e2f3e5d6f8fffeb8f1f9e0"><span class="__cf_email__" data-cfemail="deaab6bbb1bab1acb7bdf0b3bfaaaabbad9eb0b7b6f0b9b1a8">[email protected]</span></a>., and
reference E-043-2022-0.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Theodoric Mattes at 240-627-3827, or
<a href="/cdn-cgi/l/email-protection#95e1fdf0faf1fae7fcf6bbf8f4e1e1f0e6d5fbfcfdbbf2fae3"><span class="__cf_email__" data-cfemail="a5d1cdc0cac1cad7ccc68bc8c4d1d1c0d6e5cbcccd8bc2cad3">[email protected]</span></a>.
Dated: December 5, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-27114 Filed 12-8-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on December 11, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.